Argenx & their Vyvgart product is very targeted at the moment
CSL Ig products are varied & used for treating many varied conditions
Vyvgart is not a direct replacement for Ig products & is not approved to treat a wide range of conditions
Argenx has succeeded in developing a new treatment...
VYVGART is the first FDA-approved treatment of its kind for adults with anti-AChR antibody positive generalized myasthenia gravis (gMG).
Vyvgart was administered along with existing treatments - at this stage it is NOT a complete replacement & has not been approved for use in treating any other autoimmune based disorders
Amazing research & development by Argenx & doesn't seem to be of much concern to CSL Ig at this stage
UBS - CSL no need to worry about Argenx, page-4
-
- There are more pages in this discussion • 16 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$308.05 |
Change
2.510(0.82%) |
Mkt cap ! $148.8B | |||
| Open | High | Low | Value | Volume |
| $307.94 | $309.48 | $306.35 | $254.8M | 840.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 268 | $307.92 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $308.23 | 139 | 2 |
View Market Depth
| Last trade - 16.10pm 26/07/2024 (20 minute delay) ? |
| CSL (ASX) Chart |